![]() |
|
|
Vol. 297, Issue 2, 819-826, May 2001
Institut für Experimentelle und Klinische Pharmakologie und
Toxikologie, Albert-Ludwigs-Universität, Freiburg, Germany
Cannabinoids elicit marked cardiovascular responses. It is not clear
how peripheral effects on the autonomic nervous system contribute to
these responses. The aim of the present study was to characterize the
peripheral actions of cannabinoids on the autonomic innervation of the
heart. Experiments were carried out on pithed rabbits. In the first
series of experiments, postganglionic sympathetic cardioaccelerator
fibers were stimulated electrically. The synthetic cannabinoid receptor
agonists WIN55212-2 (0.005, 0.05, 0.5, and 1.5 mg kg
1
i.v.) and CP55940 (0.003, 0.03, 0.3, and 1 mg kg
1 i.v.)
dose dependently inhibited the electrically evoked cardioacceleration. The inhibition by WIN55212-2 (0.5 mg kg
1 i.v.) was
prevented by the CB1 cannabinoid receptor antagonist SR141716A (0.5 mg kg
1 i.v.). WIN55212-2 (0.5 mg
kg
1 i.v.) did not change the increase in heart rate
evoked by injection of isoprenaline. In the second series of
experiments, preganglionic vagal fibers were stimulated electrically.
WIN55212-2 (0.005, 0.05, and 0.5 mg kg
1 i.v.) and CP55940
(0.003, 0.03, and 0.3 mg kg
1 i.v.) dose dependently
inhibited the stimulation-evoked decrease in heart rate. The inhibition
produced by WIN55212-2 (0.005, 0.05, and 0.5 mg kg
1 i.v.)
was antagonized by SR141716A (0.5 mg kg
1 i.v.). The
results indicate that cannabinoids, by activating CB1
cannabinoid receptors, inhibit sympathetic and vagal neuroeffector transmission in the heart. The mechanism of the sympathoinhibition is
probably presynaptic inhibition of noradrenaline release from postganglionic sympathetic neurons. The mechanism of the inhibition of
vagal activity was not clarified: cannabinoids may have an inhibitory
action on both pre- and postganglionic vagal neurons.
This article has been cited by other articles:
![]() |
J. Tam, V. Trembovler, V. Di Marzo, S. Petrosino, G. Leo, A. Alexandrovich, E. Regev, N. Casap, A. Shteyer, C. Ledent, et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling FASEB J, January 1, 2008; 22(1): 285 - 294. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Prestifilippo, J. Fernandez-Solari, C. de la Cal, M. Iribarne, A. M. Suburo, V. Rettori, S. M. McCann, and J. C. Elverdin Inhibition of Salivary Secretion by Activation of Cannabinoid Receptors Experimental Biology and Medicine, September 1, 2006; 231(8): 1421 - 1429. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Szabo, M. Than, D. Thorn, and I. Wallmichrath Analysis of the Effects of Cannabinoids on Synaptic Transmission between Basket and Purkinje Cells in the Cerebellar Cortex of the Rat J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 915 - 925. [Abstract] [Full Text] [PDF] |
||||